These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 8302203

  • 1. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
    Prabhakaran K, Harris EB, Randhawa B, Adams LB, Williams DL, Hastings RC.
    Microbios; 1993; 76(309):251-61. PubMed ID: 8302203
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S, Marre R.
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 4. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J, Hupková M, Krcméry V.
    Cas Lek Cesk; 1995 Sep 06; 134(17):558-61. PubMed ID: 7553760
    [Abstract] [Full Text] [Related]

  • 5. Beta-lactamase inhibitors and Acinetobacter spp.
    Eng RH, Smith SM, Cherubin CE.
    J Antimicrob Chemother; 1990 Sep 06; 26(3):449-51. PubMed ID: 2172200
    [No Abstract] [Full Text] [Related]

  • 6. beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
    Prabhakaran K, Harris EB, Randhawa B, Hastings RC.
    Microbios; 1995 Sep 06; 81(328):177-85. PubMed ID: 7752957
    [Abstract] [Full Text] [Related]

  • 7. Suppression of the growth of six potentially-pathogenic mycobacteria by beta-lactam/beta-lactamase-inhibitors.
    Prabhakaran K, Harris EB, Randhawa B.
    Microbios; 1997 Sep 06; 91(366):7-14. PubMed ID: 9467917
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S, Singhal R, Sood S, Dhawan B, Das BK, Kapil A.
    Indian J Med Res; 2005 Nov 06; 122(5):425-8. PubMed ID: 16456257
    [Abstract] [Full Text] [Related]

  • 9. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas.
    WaKabongo M, Stucki ZN, Torbert DP, Olweny J.
    J Am Osteopath Assoc; 2005 Jan 06; 105(1):25-6. PubMed ID: 15710671
    [No Abstract] [Full Text] [Related]

  • 10. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI, Farooqi BJ.
    J Coll Physicians Surg Pak; 2012 Jun 06; 22(6):358-62. PubMed ID: 22630093
    [Abstract] [Full Text] [Related]

  • 11. Bactericidal action of ampicillin/sulbactam against intracellular mycobacteria.
    Prabhakaran K, Harris EB, Randhawa B.
    Int J Antimicrob Agents; 1999 Oct 06; 13(2):133-5. PubMed ID: 10595573
    [Abstract] [Full Text] [Related]

  • 12. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr 06; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG, Wisplinghoff H, Stefanik D, Seifert H.
    Antimicrob Agents Chemother; 2004 May 06; 48(5):1586-92. PubMed ID: 15105109
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT.
    Antimicrob Agents Chemother; 1989 Nov 06; 33(11):1964-9. PubMed ID: 2558615
    [Abstract] [Full Text] [Related]

  • 15. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
    Aronoff SC, Jacobs MR, Johenning S, Yamabe S.
    Antimicrob Agents Chemother; 1984 Oct 06; 26(4):580-2. PubMed ID: 6097169
    [Abstract] [Full Text] [Related]

  • 16. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA, Rudin SA, Shlaes DM.
    FEMS Microbiol Lett; 1997 Mar 01; 148(1):59-62. PubMed ID: 9066111
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of YTR 830.
    Jacobs MR, Aronoff SC, Appelbaum PC, Yamabe S.
    J Chemother; 1989 Jun 01; 1(3):151-4. PubMed ID: 2552029
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME, Marangos MN, Zhu Z, Nicolau DP, Quintiliani R, Nightingale CH.
    Antimicrob Agents Chemother; 1997 Feb 01; 41(2):435-9. PubMed ID: 9021203
    [Abstract] [Full Text] [Related]

  • 19. In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.
    Rice LB, Carias LL, Shlaes DM.
    Antimicrob Agents Chemother; 1994 Nov 01; 38(11):2663-4. PubMed ID: 7872765
    [Abstract] [Full Text] [Related]

  • 20. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli.
    Reguera JA, Baquero F, Pérez-Díaz JC, Martínez JL.
    J Antimicrob Chemother; 1991 May 01; 27(5):569-75. PubMed ID: 1653204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.